Clinical Trials

80 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-03-18

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

200 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT03598257 2026-03-17

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

300 enrolled

Inflammatory Breast Neoplasms

NCT07460752 2026-03-10

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

98 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase 2 Terminated

1 enrolled

Anatomic Stage IV Breast Cancer AJCC v8

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT06617455 2026-03-02

VEnT

Phase 2 Terminated

9 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT06224673 2026-02-13

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

36 enrolled

Triple Negative Breast Neoplasms

NCT07158021 2026-02-13

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

75 enrolled

Breast Neoplasms

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Anatomic Stage I Breast Cancer AJCC v8

NCT06860815 2026-01-28

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

11 enrolled

Breast Neoplasms

NCT05557877 2026-01-06

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

100 enrolled

Breast Neoplasms

NCT05023967 2026-01-05

Metformin and Nightly Fasting in Women With Early Breast Cancer

Carcinoma, Intraductal, Noninfiltrating

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06518057 2025-12-11

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

22 enrolled

BreastCNSThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT06910761 2025-12-08

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

35 enrolled

BreastCNSThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT06731894 2025-12-05

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

81 enrolled

Breast Neoplasms

NCT07191717 2025-11-10

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

42 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

51 enrolled

Triple Negative Breast Neoplasms

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06260033 2025-10-06

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

18 enrolled

Breast Neoplasms

NCT06525766 2025-10-03

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

35 enrolled

Breast Neoplasms

NCT06538389 2025-08-29

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

36 enrolled

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT01149083 2025-08-15

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 2 Completed

77 enrolled 17 charts

Breast Neoplasms

NCT07044310 2025-07-29

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

38 enrolled

Breast Carcinoma In Situ

NCT06113016 2025-07-08

PROFFi

164 enrolled

Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8

NCT06150898 2025-06-13

KePreSt

112 enrolled

BreastOther

Breast Neoplasms, Inflammation, Obesity

NCT06049355 2025-05-29

EMBRACE: Exercising Together

400 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Phase 2 Withdrawn